{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T13:37:21Z","timestamp":1768570641133,"version":"3.49.0"},"posted":{"date-parts":[[2025,1,25]]},"group-title":"Pharmacology and Therapeutics","reference-count":68,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T00:00:00Z","timestamp":1737763200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,1,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Understanding and predicting prescription preferences for type 2 diabetes mellitus, a heterogeneous and complex condition that affects over 10% of the global adult population, can improve prescribing practices, guide policymakers in promoting evidence-based medicine, and help tailor first-line treatments to individual characteristics or specific subgroups, improving patient outcomes. This study aimed to identify factors influencing metformin prescription, the first-line therapy recommended in Western guidelines, and to assess factors leading to its avoidance and their alignment with evidence-based medicine. It also explores factors associated with initial combination therapy, a newer and controversial approach compared to stepwise therapy.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>\n                    We performed a systematic search in PubMed, Scopus and Web of Science for observational analytical studies evaluating factors associated with metformin or combination therapy initiation. Quality assessment was done using the Joanna Briggs Institute critical appraisal checklists. (PROSPERO registry number\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42023438313\">CRD42023438313<\/jats:ext-link>\n                    ).\n                  <\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Thirty studies were included, evaluating 105 variables, mostly (62%) assessed in one study. The 25 variables using combination therapy as outcome were mostly (72%) evaluated also in one study. Initial metformin prescription was strongly associated with the age of individuals with diabetes, glycated haemoglobin levels, body mass index, and renal complications, while combination therapy was mainly linked with glycated haemoglobin levels and comorbidities. Findings also highlighted a discrepancy between clinical practice and evidence-based recommendations. However, concerns were raised regarding both the internal and external validity of the included studies.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Our systematic review, that offers insights into real-world clinical practices, indicated that there is a misalignment between clinical practices and evidence-based recommendations supporting the need for interventions of this field.<\/jats:p>\n                <\/jats:sec>","DOI":"10.1101\/2025.01.22.25320805","type":"posted-content","created":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T20:50:16Z","timestamp":1737838216000},"source":"Crossref","is-referenced-by-count":1,"title":["Factors influencing the prescription of first-line treatment for type 2 diabetes mellitus: a systematic review"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2477-482X","authenticated-orcid":false,"given":"Helena","family":"Moreira","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3452-1459","authenticated-orcid":false,"given":"Fernando","family":"Moreira","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3972-8253","authenticated-orcid":false,"given":"\u00c2ngelo","family":"Jesus","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4586-2910","authenticated-orcid":false,"given":"Matilde","family":"Monteiro-Soares","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2362-5527","authenticated-orcid":false,"given":"Paulo","family":"Santos","sequence":"additional","affiliation":[]}],"member":"54368","reference":[{"key":"2025012800151093000_2025.01.22.25320805v1.1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21051664"},{"key":"2025012800151093000_2025.01.22.25320805v1.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.109119"},{"key":"2025012800151093000_2025.01.22.25320805v1.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2020.108086"},{"key":"2025012800151093000_2025.01.22.25320805v1.4","doi-asserted-by":"publisher","DOI":"10.2337\/DCI22-0034"},{"key":"2025012800151093000_2025.01.22.25320805v1.5","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2020-001279"},{"key":"2025012800151093000_2025.01.22.25320805v1.6","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-S009"},{"key":"2025012800151093000_2025.01.22.25320805v1.7","unstructured":"(NICE) LNI for H and CE. Type 2 diabetes in adults: management. NICE Guideline, No. 28. DOI: 32023018."},{"key":"2025012800151093000_2025.01.22.25320805v1.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.healthpol.2013.08.002"},{"key":"2025012800151093000_2025.01.22.25320805v1.9","first-page":"1121","article-title":"Understanding of regional variation in the use of surgery. Lancet (London","volume":"382","year":"2013","journal-title":"England"},{"key":"2025012800151093000_2025.01.22.25320805v1.10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"2025012800151093000_2025.01.22.25320805v1.11","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4"},{"key":"2025012800151093000_2025.01.22.25320805v1.12","doi-asserted-by":"publisher","DOI":"10.46658\/JBIMES-20-01"},{"key":"2025012800151093000_2025.01.22.25320805v1.13","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/pds.2262","article-title":"Initial and subsequent therapy for newly diagnosed type 2 diabetes patients treated in primary care using data from a vendor-based electronic health record","volume":"21","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025012800151093000_2025.01.22.25320805v1.14","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1463-1326.2011.01498.x","article-title":"Time to treatment initiation with oral antihyperglycaemic therapy in US patients with newly diagnosed type 2 diabetes. Diabetes","volume":"14","year":"2012","journal-title":"Obes Metab"},{"key":"2025012800151093000_2025.01.22.25320805v1.15","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6823-12-1"},{"key":"2025012800151093000_2025.01.22.25320805v1.16","doi-asserted-by":"publisher","DOI":"10.1177\/1060028013503624"},{"key":"2025012800151093000_2025.01.22.25320805v1.17","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.diabres.2014.07.014","article-title":"Patterns and determinants of new first-line antihyperglycaemic drug use in patients with type 2 diabetes mellitus","volume":"106","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"key":"2025012800151093000_2025.01.22.25320805v1.18","unstructured":"Wright AK . Examining Drug Utilisation Patterns and Optimal Treatment Pathways of Antidiabetic Medications. The University of Manchester, https:\/\/pure.manchester.ac.uk\/ws\/portalfiles\/portal\/54566935\/FULL_TEXT.PDF (2014)."},{"key":"2025012800151093000_2025.01.22.25320805v1.19","doi-asserted-by":"publisher","DOI":"10.1159\/000382900"},{"key":"2025012800151093000_2025.01.22.25320805v1.20","doi-asserted-by":"publisher","DOI":"10.7488\/era\/869"},{"key":"2025012800151093000_2025.01.22.25320805v1.21","doi-asserted-by":"crossref","first-page":"110777","DOI":"10.1016\/j.diabres.2023.110777","article-title":"Longitudinal treatment patterns in patients recently diagnosed with type 2 diabetes mellitus in Catalonia","volume":"202","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"key":"2025012800151093000_2025.01.22.25320805v1.22","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/pds.2059","article-title":"Guideline-conformity of initiation with oral hypoglycemic treatment for patients with newly therapy-dependent type 2 diabetes mellitus in Austria","volume":"20","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025012800151093000_2025.01.22.25320805v1.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2011.07.033"},{"key":"2025012800151093000_2025.01.22.25320805v1.24","first-page":"1","article-title":"Treatment patterns of drug-naive patients with type 2 diabetes mellitus: A retrospective cohort study using a Japanese hospital database","volume":"11","year":"2019","journal-title":"Diabetol Metab Syndr"},{"key":"2025012800151093000_2025.01.22.25320805v1.25","doi-asserted-by":"crossref","first-page":"375","DOI":"10.20344\/amp.10414","article-title":"Initial Therapeutic Choices for Type 2 Diabetes in the Portuguese Sentinel Practice Network","volume":"32","year":"2019","journal-title":"Acta Med Port"},{"key":"2025012800151093000_2025.01.22.25320805v1.26","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00968"},{"key":"2025012800151093000_2025.01.22.25320805v1.27","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph17103742"},{"key":"2025012800151093000_2025.01.22.25320805v1.28","first-page":"1","article-title":"Real-world Observational Study on Patient Outcomes in Diabetes (RESPOND): Study design and baseline characteristics of patients with type 2 diabetes newly initiating oral antidiabetic drug monotherapy in Japan","volume":"8","year":"2020","journal-title":"BMJ Open Diabetes Res Care"},{"key":"2025012800151093000_2025.01.22.25320805v1.29","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1111\/dme.14149","article-title":"Pharmacological treatment initiation for type 2 diabetes in Australia: are the guidelines being followed?","volume":"37","year":"2020","journal-title":"Diabet Med"},{"key":"2025012800151093000_2025.01.22.25320805v1.30","doi-asserted-by":"publisher","DOI":"10.1111\/dme.14622"},{"key":"2025012800151093000_2025.01.22.25320805v1.31","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-2926"},{"key":"2025012800151093000_2025.01.22.25320805v1.32","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1016\/j.numecd.2021.06.006","article-title":"Initial treatment of diabetes in Italy. A nationwide population-based study from of the ARNO Diabetes Observatory","volume":"31","year":"2021","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2025012800151093000_2025.01.22.25320805v1.33","doi-asserted-by":"publisher","DOI":"10.1055\/a-1927-4454"},{"key":"2025012800151093000_2025.01.22.25320805v1.34","first-page":"1000","article-title":"Initial therapy, persistence and regimen change in a cohort of newly treated type 2 diabetes patients","volume":"79","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"2025012800151093000_2025.01.22.25320805v1.35","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13636"},{"key":"2025012800151093000_2025.01.22.25320805v1.36","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.jcjd.2013.04.008","article-title":"Use patterns of antidiabetic regimens by patients with type2 diabetes","volume":"37","year":"2013","journal-title":"Can J Diabetes"},{"key":"2025012800151093000_2025.01.22.25320805v1.37","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1186\/1472-6963-13-442","article-title":"Guidelines adherence in the treatment of patients with newly diagnosed type 2 diabetes: a historical cohort comparing the use of metformin in Quebec pre and post-Canadian Diabetes Association guidelines","volume":"13","year":"2013","journal-title":"BMC Health Serv Res"},{"key":"2025012800151093000_2025.01.22.25320805v1.38","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1185\/03007995.2013.827108","article-title":"Glycemic control and the first use of oral antidiabetic agents among patients with type 2 diabetes mellitus","volume":"29","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"2025012800151093000_2025.01.22.25320805v1.39","first-page":"2036","article-title":"Learning Effective Treatment Pathways for Type-2 Diabetes from a clinical data warehouse","volume":"2016","year":"2016","journal-title":"AMIA . Annu Symp proceedings AMIA Symp"},{"key":"2025012800151093000_2025.01.22.25320805v1.40","doi-asserted-by":"crossref","first-page":"e6122","DOI":"10.1097\/MD.0000000000006122","article-title":"Comparison of baseline characteristics and clinical course in Japanese patients with type 2 diabetes among whom different types of oral hypoglycemic agents were chosen by diabetes specialists as initial monotherapy (JDDM 42)","volume":"96","year":"2017","journal-title":"Medicine (Baltimore"},{"key":"2025012800151093000_2025.01.22.25320805v1.41","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/jdi.12567","article-title":"Prescription of oral hypoglycemic agents for patients with type 2 diabetes mellitus: A retrospective cohort study using a Japanese hospital database","volume":"8","year":"2017","journal-title":"J Diabetes Investig"},{"key":"2025012800151093000_2025.01.22.25320805v1.42","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.puhe.2017.06.008","article-title":"Prescription trends and the selection of initial oral antidiabetic agents for patients with newly diagnosed type 2 diabetes: a nationwide study","volume":"152","year":"2017","journal-title":"Public Health"},{"key":"2025012800151093000_2025.01.22.25320805v1.43","doi-asserted-by":"publisher","DOI":"10.1201\/9781003039648-ch2"},{"key":"2025012800151093000_2025.01.22.25320805v1.44","unstructured":"Centers for Medicare & Medicaid Services. What\u2019s Medicare?, https:\/\/www.medicare.gov\/ (accessed 7 December 2024)."},{"key":"2025012800151093000_2025.01.22.25320805v1.45","doi-asserted-by":"crossref","first-page":"e14370","DOI":"10.1097\/MD.0000000000014370","article-title":"The prescription pattern of initial treatment for type 2 diabetes in Beijing from 2011 to 2015","volume":"98","year":"2019","journal-title":"Medicine (Baltimore"},{"key":"2025012800151093000_2025.01.22.25320805v1.46","doi-asserted-by":"crossref","unstructured":"Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, Cheng AYY. Diabetes Canada 2018 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J diabetes 2018; 42 (Suppl: S1\u2013S325.","DOI":"10.1016\/S1499-2671(17)31026-2"},{"key":"2025012800151093000_2025.01.22.25320805v1.47","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13306"},{"key":"2025012800151093000_2025.01.22.25320805v1.48","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad192"},{"key":"2025012800151093000_2025.01.22.25320805v1.49","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13098-019-0476-0","article-title":"Consensus recommendations for management of patients with type 2 diabetes mellitus and cardiovascular diseases","volume":"11","year":"2019","journal-title":"Diabetol Metab Syndr"},{"key":"2025012800151093000_2025.01.22.25320805v1.50","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jsps.2021.12.019","article-title":"Prescribing patterns of antidiabetics in type 2 diabetes and factors affecting them","volume":"30","year":"2022","journal-title":"Saudi Pharm J"},{"key":"2025012800151093000_2025.01.22.25320805v1.51","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.1.98"},{"key":"2025012800151093000_2025.01.22.25320805v1.52","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph17072602"},{"key":"2025012800151093000_2025.01.22.25320805v1.53","doi-asserted-by":"crossref","first-page":"e0290692","DOI":"10.1371\/journal.pone.0290692","article-title":"Demographic and socioeconomic determinants of access to care: A subgroup disparity analysis using new equity-focused measurements","volume":"18","year":"2023","journal-title":"PLoS One"},{"key":"2025012800151093000_2025.01.22.25320805v1.54","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.diabres.2015.02.027","article-title":"Why physicians do not initiate dual therapy as recommended by AACE guidelines: A survey of clinicians in the United States","volume":"108","year":"2015","journal-title":"Diabetes Res Clin Pract"},{"key":"2025012800151093000_2025.01.22.25320805v1.55","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-1299"},{"key":"2025012800151093000_2025.01.22.25320805v1.56","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3389\/fendo.2020.00191","article-title":"Metformin and Its Benefits for Various Diseases","volume":"11","year":"2020","journal-title":"Front Endocrinol (Lausanne"},{"key":"2025012800151093000_2025.01.22.25320805v1.57","first-page":"579","article-title":"HYPOGLYCEMIA INDUCED BY ANTIDIABETIC SULFONYLUREAS","volume":"119","year":"2015","journal-title":"Rev Med Chir Soc Med Nat Iasi"},{"key":"2025012800151093000_2025.01.22.25320805v1.58","unstructured":"Dire\u00e7\u00e3o-Geral da Sa\u00fade . Abordagem Terap\u00eautica Farmacol\u00f3gica na Diabetes Mellitus Tipo 2 no Adulto. Norma da Dire\u00e7\u00e3o-Geral da S no 052\/2011 atualizada a 27\/04\/2015 2015; 1\u201328."},{"key":"2025012800151093000_2025.01.22.25320805v1.59","doi-asserted-by":"publisher","DOI":"10.2337\/dci17-0003"},{"key":"2025012800151093000_2025.01.22.25320805v1.60","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-013-2856-6"},{"key":"2025012800151093000_2025.01.22.25320805v1.61","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-008-1157-y"},{"key":"2025012800151093000_2025.01.22.25320805v1.62","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-2231"},{"key":"2025012800151093000_2025.01.22.25320805v1.63","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-154-8-201104190-00007"},{"key":"2025012800151093000_2025.01.22.25320805v1.64","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000350"},{"key":"2025012800151093000_2025.01.22.25320805v1.65","doi-asserted-by":"publisher","DOI":"10.1016\/j.kisu.2021.11.003"},{"key":"2025012800151093000_2025.01.22.25320805v1.66","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s10198-017-0926-2","article-title":"Determinants of health care costs in the senior elderly: age, comorbidity, impairment, or proximity to death?","volume":"19","year":"2018","journal-title":"Eur J Health Econ"},{"key":"2025012800151093000_2025.01.22.25320805v1.67","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afac155"},{"key":"2025012800151093000_2025.01.22.25320805v1.68","doi-asserted-by":"crossref","first-page":"e13997","DOI":"10.1111\/eci.13997","article-title":"Meta-analysis of factors associated with antidiabetic drug prescribing for type 2 diabetes mellitus","volume":"53","year":"2023","journal-title":"Eur J Clin Invest"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2025.01.22.25320805","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T20:26:07Z","timestamp":1768508767000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2025.01.22.25320805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,25]]},"references-count":68,"URL":"https:\/\/doi.org\/10.1101\/2025.01.22.25320805","relation":{},"subject":[],"published":{"date-parts":[[2025,1,25]]},"subtype":"preprint"}}